Pfizer jumps on the scene in RSV, pushing vaccine candidate into human testing

Pfizer is counting on several mid- and late-stage vaccine candidates to carry the torch after its megablockbuster pneumococcal shot Prevnar 13, the world's bestselling vaccine, slows down. B…
Read the full story: FiercePharma: Pharma